Impact of gestrinone on the course of asymptomatic endometriosis.

A new drug, gestrinone, was subjected to the first double blind, randomised placebo controlled trial of any treatment of endometriosis. The disease deteriorated in eight (47%) of the 17 patients prescribed placebo (95% confidence limits 23% and 71%) compared with none of the 18 patients prescribed gestrinone (p = 0.002). There was a difference in elimination of the endometriosis in the gestrinone group compared with placebo but this was not statistically significant (p = 0.057). There was a significant difference in improvement of the disease in the gestrinone group compared with placebo (p = 0.004), confirming that gestrinone is an effective treatment of endometriosis. Endometriosis deteriorates in at least 23% of patients; as it is impossible to predict in whom this will happen, treatment appears to be warranted in all cases.
AuthorsE J Thomas, I D Cooke
JournalBritish medical journal (Clinical research ed.) (Br Med J (Clin Res Ed)) Vol. 294 Issue 6567 Pg. 272-4 (Jan 31 1987) ISSN: 0267-0623 [Print] ENGLAND
PMID3101839 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Norpregnatrienes
  • Gestrinone
  • Adult
  • Clinical Trials as Topic
  • Double-Blind Method
  • Endometriosis (drug therapy)
  • Female
  • Gestrinone (therapeutic use)
  • Humans
  • Norpregnatrienes (therapeutic use)
  • Random Allocation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: